Marketing-authorisation holder · Germany
Cheplapharm Registration Gmbh
78 medicines in 6 countries, as authorisation holder and manufacturer.
Loading your page…
Loading your page…
Marketing-authorisation holder · Germany
78 medicines in 6 countries, as authorisation holder and manufacturer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 78
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| OLANZAPINA CHEPLAPHARMCompressa rivestita | Olanzapine | Italy | Authorised | |
| Roaccutane 10 mg meke kapsulekapsula, meka | Isotretinoin | Croatia | Marketed | 2024 |
| Tarceva | Erlotinib | EU (EMA) | Authorised | 2005 |
| TARCEVACompressa rivestita con film | Erlotinib | Italy | Authorised | |
| TARCEVA 100 mg COMPRIMIDOS RECUBIERTOS CON PELICULA100 mg · Comprimido recubierto | Erlotinib | Spain | Marketed | 2005 |
| Tarceva 100 mg, filmomhulde tablettenFilmomhulde tablet | Erlotinib | Netherlands | Authorised | 2005 |
| TARCEVA 150 mg COMPRIMIDOS RECUBIERTOS CON PELICULA150 mg · Comprimido recubierto | Erlotinib | Spain | Marketed | 2005 |
| Tarceva 150 mg, filmomhulde tablettenFilmomhulde tablet | Erlotinib | Netherlands | Authorised | 2005 |
| TARCEVA 25 mg COMPRIMIDOS RECUBIERTOS CON PELICULA25 mg · Comprimido recubierto | Erlotinib | Spain | Marketed | 2005 |
| Tarceva 25 mg, filmomhulde tablettenFilmomhulde tablet | Erlotinib | Netherlands | Authorised | 2005 |
| Zypadhera | Olanzapine | EU (EMA) | Authorised | 2008 |
| ZYPADHERAPolvere e solvente per sospensione iniettabile a rilascio prolungato | Olanzapine | Italy | Authorised | |
| Zypadhera 210 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgiftePoeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte | Olanzapine | Netherlands | Authorised | 2008 |
| ZYPADHERA 210 mg POLVO Y DISOLVENTE PARA SUSPENSION INYECTABLE DE LIBERACION PROLONGADA210 mg · Polvo y disolvente para suspensión inyectable de liberación prolongada | Olanzapine | Spain | Marketed | 2010 |
| Zypadhera 300 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgiftePoeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte | Olanzapine | Netherlands | Authorised | 2008 |
| ZYPADHERA 300 mg POLVO Y DISOLVENTE PARA SUSPENSION INYECTABLE DE LIBERACION PROLONGADA300 mg · Polvo y disolvente para suspensión inyectable de liberación prolongada | Olanzapine | Spain | Marketed | 2010 |
| Zypadhera 405 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgiftePoeder en oplosmiddel voor suspensie voor injectie met verlengde afgifte | Olanzapine | Netherlands | Authorised | 2008 |
| ZYPADHERA 405 mg POLVO Y DISOLVENTE PARA SUSPENSION INYECTABLE DE LIBERACION PROLONGADA405 mg · Polvo y disolvente para suspensión inyectable de liberación prolongada | Olanzapine | Spain | Marketed | 2010 |
| ZYPREXA20 mg · Tablet | Olanzapine | Canada | Marketed | 2007 |
| ZYPREXA5 mg · Tablet | Olanzapine | Canada | Marketed | 1996 |
| ZYPREXA2.5 mg · Tablet | Olanzapine | Canada | Marketed | 1997 |
| ZYPREXA15 mg · Tablet | Olanzapine | Canada | Marketed | 2002 |
| ZYPREXA7.5 mg · Tablet | Olanzapine | Canada | Marketed | 1996 |
| Zyprexa | Olanzapine | EU (EMA) | Authorised | 1996 |
| ZYPREXA10 mg · Tablet | Olanzapine | Canada | Marketed | 1996 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 41 | 41 | 0 | CompaniesAll medicines |
| Netherlands | 17 | 17 | 0 | CompaniesAll medicines |
| Canada | 11 | 11 | 0 | CompaniesAll medicines |
| European Union (EMA) | 4 | 4 | 0 | CompaniesAll medicines |
| Italy | 4 | 4 | 0 | CompaniesAll medicines |
| Croatia | 1 | 1 | 0 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
HALMED, Baza lijekova, source export 08.10.2026., acquired 2026-10-08; factual structured adaptation; Otvorena dozvola RH, NN 67/2017.
Licence: Otvorena dozvola RH
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_A_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:41 GMT; acquired 2026-10-13T17:21:06.055244+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Report an error or request removalCorrections from the company itself are welcome.
Ranked by their number of medicines.